ERBB2 and breast cancer: Pertuzumab is being further evaluated in the following clinical trials: MARIANNE, for advanced breast cancer, NEOSPHERE, for early breast cancer, TRYPAHENA, for HER2+ stage II/III breast cancer and APHINITY for HER2+ nonmetastatic breast cancer [270].